Search research articles
Contact Us
Filters
Showing results (111-120 of 164) with videos related to
Page
of 17
Sort By:
Blood and Lymphatic Cancer : Targets and Therapy
|
September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Chaitra Ujjani, Anthony Mato, Brian T Hill, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Science Immunology
|
June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
Blood
|
February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
Anas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
British Journal of Haematology
|
March 26, 2014
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
Tatyana Feldman, Anthony R Mato, Kar F Chow, et al.
Blood
|
April 30, 2010
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
Violetta V Leshchenko, Pei-Yu Kuo, Rita Shaknovich, et al.
Oncology Reports
|
July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
Nam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Laurie H Sehn, Andre Goy, Fritz C Offner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
Jorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Page
of 17
Search research articles
Search
Showing results (111-120 of 164) with videos related to
Sort By:
Page
of 17
Blood and Lymphatic Cancer : Targets and Therapy
|
September 18, 2020
The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
Chaitra Ujjani, Anthony Mato, Brian T Hill, et al.
British Journal of Haematology
|
March 4, 2014
Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study
Michael Wang, Leslie L Popplewell, Robert H Collins, et al.
Science Immunology
|
June 7, 2020
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Mark Roschewski, Michail S Lionakis, Jeff P Sharman, et al.
Blood
|
February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma
Anas Younes, Yasuhiro Oki, Peter McLaughlin, et al.
British Journal of Haematology
|
March 26, 2014
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma
Tatyana Feldman, Anthony R Mato, Kar F Chow, et al.
Blood
|
April 30, 2010
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
Violetta V Leshchenko, Pei-Yu Kuo, Rita Shaknovich, et al.
Oncology Reports
|
July 29, 2003
Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes
Nam H Dang, Fredrick B Hagemeister, Madeleine Duvic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Laurie H Sehn, Andre Goy, Fritz C Offner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 8, 2005
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
Jorge E Romaguera, Luis Fayad, Maria A Rodriguez, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Page
of 17